Waiting list

14 May 10:00Operaterrassen

Welcome to Flerie’s portfolio company presentations

We are pleased to invite you to an exclusive event with portfolio company presentations at Operaterrassen in Stockholm on May 14, 2025. This event provides private and institutional investors, as well as industry executives, strategic updates, insights into a selection of Flerie’s portfolio companies, and the opportunity to engage with key leaders shaping the future of life sciences.

Hear directly from Flerie’s CEO, Ted Fjällman, as he presents the company’s vision and strategy. In addition, select CEOs from Flerie’s portfolio companies will highlight their innovations and growth potential.

We look forward to welcoming you to this insightful and engaging event.

Portfolio Company Presentations

The event will be held at Operaterrassen in Stockholm between 10:00-11:00 CEST on May 14, 2025. Flerie’s CEO Ted Fjällman will present the company’s strategy, accompanied by presentations from the CEOs of selected Flerie portfolio companies.

We invite all event participants to join us for lunch at Operaterrassen at 12:00 CEST, following the Annual General Meeting (AGM), which will be held separately for Flerie shareholders. Non-shareholders attending the event will have the opportunity to network and mingle during the AGM.

RSVP required. Please confirm your attendance at your earliest convenience.

Annual General Meeting
The event will be held in conjunction with the Annual General Meeting of Flerie AB. Shareholders who wish to attend the Annual General Meeting must register in accordance with the notification to attend the AGM.  

Link to the notification to attend the AGM: Notice to attend the AGM


Waiting list
© MapTiler © OpenStreetMap contributors

Speakers

Ted Fjällman, CEO
Flerie

Flerie

Flerie is an active long-term life science investor, with a broad and diversified portfolio of innovative companies based on pioneering science. We invest in product development and commercial growth opportunities globally alongside other leading investors, focusing predominantly on private companies that are otherwise difficult to access. Flerie’s active ownership model, broad network and resources support and accelerate the development of the portfolio projects, creating value for shareholders. Flerie AB’s ordinary share is listed on Nasdaq Stockholm with the ticker FLERIE. For further information please visit www.flerie.com

Read more

Alexandra Ekman Ryding, CEO
Atrogi

Atrogi
First-in-class oral treatments designed to transform the management of diabetes, obesity, and other metabolic disorders.

Metabolic disorders such as obesity and type 2 diabetes are becoming a global epidemic, affecting people’s health and putting a significant financial burden on healthcare systems worldwide. More than half a billion people are currently living  with type 2 diabetes worldwide, and it is projected that obesity will affect over half of the world’s population by 2035.

Atrogi’s technology platform, is based on an innovative concept of stimulating the β2-adrenergic receptor to address various metabolic disorders, including type 2 diabetes, obesity, and muscle-wasting conditions. The company’s lead asset, ATR-258, has successfully completed a Phase I safety study involving both healthy volunteers and individuals with type 2 diabetes. This first-in-class, once-daily oral treatment will offer significant advantages in patient adherence and convenience compared to injectable therapies.

Atrogi is a privately held company based in Stockholm, Sweden.

Read more

Johan Seijmer, CEO
Chromafora

Chromafora 

Cleantech innovation based on novel technologies that clean water from hazardous PFAS. PFAS are synthetic chemicals widely used in consumer products, known for their persistence in the environment. Along with heavy metals, these “forever chemicals” have been linked to a range of severe health issues, including cancer, disruptions to the reproductive system, and a weakened immune system. Their widespread presence and potential health risks have raised significant concerns among scientists and public health authorities.

Chromafora develops unique methods to clean water from PFAS and heavy metals and collect and recirculate valuable minerals such as gold and rare earth metals. To this end, Chromafora offers SELMEXT and SELPAXT, which target earth metals and PFAS to industrial and institutional actors that work with or utilise water in their processes. By tackling these persistent environmental pollutants, Chromafora’s technologies contribute to mitigating health risks while offering sustainable water treatment.

Chromafora is a privately held company based in Stockholm, Sweden.

Read more

Niranjan Y. Sardesai, CEO
Geneos Therapeutics

Geneos Therapeutics

Personalised cancer immunotherapies based on a patient’s complete tumour neoantigen repertoire – first applied to liver cancer.

Cancer is characterised by uncontrolled cell growth due to mutations. Malignant cells escape the immune system, leading to the formation of tumours that vary in treatability. Hepatocellular carcinoma (HCC), a common type of liver cancer, is one of the most aggressive cancers, and despite significant advancements in treatment in recent years, there is a lack of effective treatment options for patients. 

Geneos Therapeutics has developed a proprietary platform, GT-EPIC™, to create novel and distinctly personalised cancer immunotherapies that have already been shown to save the lives of advanced HCC patients. The company’s strategy centres on targeting all of a patient’s self-antigens (mutations) produced by individual patient’s tumour cells – neoantigens – thus reducing the chance of ‘tumour escape’ to a minimum. The immunotherapies target solid tumours, beginning with hepatocellular carcinoma, the most common type of primary liver cancer. However, the technology is broadly applicable to essentially any type of cancer. The very promising results from the company’s phase Ib/IIa trial involving second-line HCC patients was published in Nature Medicine and demonstrated several complete responses that suggest a potential cure for a patient group with a historically poor prognosis.

Geneos Therapeutics is a privately held company based in Philadelphia, USA.

Read more

Janet Hoogstrate, CEO
NorthX Biologics

NorthX Biologics

Advanced biologics manufacturer offering customers a Beyond CDMO® approach to process development, clinical manufacturing and commercial supply.

The development and production of advanced therapeutics, such as recombinant proteins, nucleic acids (DNA and RNA), and cell and gene therapies, including viral vectors, is riddled with challenges. To enhance project efficiency and reduce costs arising from avoidable errors, biotech companies engage specialised contract development and manufacturing organisations (CDMOs).

NorthX Biologics is an industry-leading CDMO that provides comprehensive services from R&D to commercial manufacturing. Beyond CDMO® stands for a partnership in the truest sense, where clients work closely with experienced teams at NorthX to overcome development challenges. Its manufacturing and analytical services cover a wide range of biologics, including plasmid DNA, mRNA, recombinant proteins, viral vectors, and cell therapies. NorthX offers tailored and complete solutions in biologics manufacturing to its various customers, which range from academic reseachers and small biotech to large biopharma companies. By adapting its infrastructure and processes to accommodate evolving demands, the company is employing its business model to lead the industry’s shift toward personalised therapies.

NorthX Biologics is a privately held company based in Matfors and Stockholm, Sweden.

Read more

Fleriecontact@flerie.com